Cingulate Inc. (CING) Stock

Cingulate Inc. (CING) is a Healthcare stock trading at $5.54 (as of 2026-08-21), with a market capitalization of $80.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Cingulate Inc. is a clinical-stage biopharmaceutical company developing therapies for attention-deficit/hyperactivity disorder and anxiety disorders. Its main candidates include CTx-1301 (dexmethylphenidate, in phase 3), CTx-1302 (dextroamphetamine), and CTx-2103 for anxiety conditions.

Understand Cingulate Inc.: how it makes money

Cingulate Inc. develops clinical-stage biopharmaceutical product candidates for attention-deficit/hyperactivity disorder and anxiety, aiming to generate value by successfully advancing these programs through clinical trials and, if approved, commercializing them.

Because Cingulate is clinical-stage, its long-term profit model depends primarily on the clinical and regulatory success of its product candidates (CTx-1301 in phase 3, plus earlier-stage programs like CTx-1302 and CTx-2103), rather than on current product sales.

Business quality (Weak): Limited investor-facing operating detail in the provided facts, no reportable segments, and only market size metrics are available as KPIs, so conclusions must rely on pipeline stage and the lack of revenue.

Bull case

  • Advancing development in a major indication: CTx-1301 (dexmethylphenidate) is in phase 3 clinical trial for attention-deficit/hyperactivity disorder.
  • Broader pipeline across related disorders: CTx-1302 (dextroamphetamine) targets attention-deficit/hyperactivity disorders, and CTx-2103 targets anxiety disorders.
  • Large addressable anxiety market, per provided data: The Worldwide Anxiety Market Size is listed as USD 11.6B.

Bear case

  • No demonstrated revenue in the provided period: Revenue is shown as 0.0B for the 2025-06-30 period.
  • Significant operating losses in the provided period: Operating margin is shown as -4998.3% for the 2025-06-30 period.
  • Clinical and regulatory outcome risk: As a clinical-stage company, success is not assured and key candidates must pass clinical trial and approval hurdles before they can drive commercialization.
  • Market size does not guarantee product success: Even with a stated market size, outcomes depend on clinical efficacy, safety, and the ability to compete after approval.
Valuation — source: SEC EDGAR (first-party)
Price$5.54
Market Cap$80.49M
Price / Book3.43
FCF Yield-50.4%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD CAPITAL MANAGEMENT LLC ($1.92M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOShane J. Schaffer
Employees13
CountryUS
IPO Date2021-12-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • MAIA Biotechnology, Inc. (MAIA)
  • LifeVantage Corporation (LFVN)
  • Dogwood Therapeutics, Inc. (DWTX)
  • Verrica Pharmaceuticals Inc. (VRCA)
  • Elicio Therapeutics, Inc. (ELTX)
  • Lunai Bioworks Inc. (LNAI)
  • Annovis Bio, Inc. (ANVS)
  • Telomir Pharmaceuticals, Inc. Common Stock (TELO)
CING earnings history · CING institutional & insider holders · CING KPIs & operating metrics · CING financials · CING investor presentations & press releases · CING SEC filings · CING peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.